Skip to content

Biosimilars Council applauds patent abuse act

The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.

Table of Contents

WASHINGTON, DC — The Biosimilars Council applauds the unanimous Senate passage of the Affordable Prescriptions for Patients Act led by Senator Cornyn (R-TX) and Senator Blumenthal (D-CT). The bill is aimed at reforming patent abuse in the pharmaceutical industry.“The Biosimilars Council and AAM applauds unanimous Senate passage of the Cornyn-Blumenthal legislation,” said Craig Burton, executive director of the biosimilars council. “Patent thickets are used by brand pharmaceutical companies to maintain high prices and deny patients access to lower-cost medicines. This legislation is a great step in curbing these abuses and will help increase competition and access for biosimilars. We encourage the House to take up this legislation and for Congress to continue working to help lower costs for patients.”

Comments

Latest